1.	A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18491, NCT00118755
2.	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18527, NCT00121836
3.	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML18530, NCT00127933
4.	Phase II/III Randomized Study of Capecitabine Versus Vinorelbine in Women With Metastatic Breast Cancer Previously Treated With Taxanes With or Without Anthracyclines Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-10001, EORTC-16001O, IDBBC-EORTC-10001, NCT00049660
5.	Weekly Taxol Plus Xeloda® vs Taxotere q3wk Plus Xeloda® in the Treatment of Metastatic BC Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: NBCG10, REK 378-04-03133, NMA 03-07568, NCT00201435
6.	The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: AG0501CR, NCT00294359
7.	Phase III Open Label Randomized Study Comparing Capecitabine and Fluorouracil in Combination With Leucovorin Calcium as First Line Chemotherapy in Patients With Advanced and/or Metastatic Colorectal Carcinoma (Summary Last Modified 05/98) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-SO14695, NCI-V97-1320
8.	Phase III Randomized Study of Adjuvant Capecitabine Versus Fluorouracil and Low-Dose Leucovorin Calcium in Chemotherapy Naive Patients With Previously Resected Stage III Colon Cancer (Summary Last Modified 12/2001) Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: ROCHE-M66001, NCT00009737
9.	Phase III Randomized Study of Bevacizumab With Capecitabine Versus Capecitabine Alone in Women With Previously Treated Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: GENENTECH-AVF2119g, GUMC-00299, MSKCC-01008, UAB-0028, UAB-F001009003, NCT00012285
10.	Phase III Randomized Study of Adjuvant Chemotherapy Comprising Standard Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC) Versus Oral Capecitabine in Elderly Women With Operable Adenocarcinoma of the Breast Phase: Phase III Type: Treatment Status: Closed Age: 65 and over Sponsor: NCI Protocol IDs: CALGB-49907, ECOG-CALGB-49907, CAN-NCIC-MAC1, SWOG-CALGB-49907, NCT00024102, MAC1
11.	Phase III Randomized Study of Gemcitabine With or Without Capecitabine in Patients With Advanced Pancreatic Cancer Phase: Phase III Type: Treatment Status: Closed Age: Over 18 Sponsor: Other Protocol IDs: SWS-SAKK-44/00, CECOG/PAN-1.3.001, EU-20142, NCT00030732
12.	Phase III Randomized Study of Gemcitabine With or Without Capecitabine in Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Other Protocol IDs: CRUK-GEM-CAP, EU-20116, ISRCTN11513444, NCT00032175
13.	Phase III Randomized Study of Oxaliplatin and Bevacizumab (Avastin™) With Fluorouracil and Leucovorin Calcium or Capecitabine in Patients With Advanced Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PROLOGUE-SANOFI-ARD5099, SANOFI-ARD5099, NCT00062426
14.	Phase III Randomized Study of Irinotecan and Capecitabine Versus Irinotecan, Leucovorin Calcium, and Fluorouracil With Versus Without Celecoxib in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-40015, NCT00064181
15.	Phase III Randomized Study of Adjuvant Irinotecan, Fluorouracil, and Leucovorin Calcium Versus Oxaliplatin, Fluorouracil, and Leucovorin Calcium Versus Fluorouracil and Leucovorin Calcium in Patients With Stage II or III Rectal Cancer Receiving Combined Radiotherapy and Fluorouracil Either Preoperatively or Postoperatively Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ECOG-E3201, E3201, NCT00068692
16.	Phase III Randomized Study of Fluorouracil, Leucovorin Calcium, Oxaliplatin, and Bevacizumab Versus Capecitabine, Oxaliplatin, and Bevacizumab in Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0303, S0303, ECOG-S0303, NCT00070122
17.	A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16966, NCT00069095
18.	A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NO16967, NCT00069108
19.	Phase III Randomized Study of Adjuvant Oxaliplatin and Capecitabine Versus Fluorouracil and Leucovorin Calcium in Chemotherapy-Naïve Patients With Resected Stage III Colon Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0310023, ROCHE-NO16968, NCT00080691
20.	Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA163-046, NCT00080301
21.	Phase III Randomized Study of Capecitabine With Versus Without Lapatinib in Women With Refractory Locally Advanced or Metastatic Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GSK-EGF100151, UCLA-0403074-01, NCT00078572
22.	Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA163-048, NCT00082433
23.	A Study of Xeloda (Capecitabine) in Women With High-Risk Breast Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: NO17629, NCT00089479
24.	Phase III Randomized Study of Adjuvant Oxaliplatin, Leucovorin Calcium, and Fluorouracil (FOLFOX-4) Versus Bevacizumab and FOLFOX-4 Versus Bevacizumab, Oxaliplatin, and Capecitabine in Patients With High-Risk Stage II or Stage III Colon Cancer Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0412086-01, ROCHE-BO17920A, NCT00112918
25.	Docetaxel Followed by CEF (Cyclophosphamide, Epirubicin and 5-Fluorouracil) Compared to Docetaxel and Capecitabine Followed by CEX (Cyclophosphamide, Epirubicin and Capecitabine) as Adjuvant Treatment for Breast Cancer Phase: Phase III Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: FBCG Protocol No. 01-2003, Roche protocol number MO17728, NCT00114816